GLP-1 Medications: Two Different Coverage Scenarios
GLP-1 receptor agonist medications include drugs approved for two distinct purposes:
- Type 2 diabetes: Ozempic (semaglutide), Trulicity (dulaglutide),
Victoza (liraglutide), Rybelsus (oral semaglutide), and Mounjaro (tirzepatide)
are FDA-approved for type 2 diabetes management. Most commercial health plans
cover diabetes medications with appropriate prior authorization.
- Weight management: Wegovy (high-dose semaglutide) and Zepbound
(tirzepatide) are FDA-approved specifically for chronic weight management. Coverage
for weight loss medications is much less consistent — and is where most
coverage controversies arise.
The critical distinction: the same molecule (semaglutide in Ozempic vs. Wegovy,
tirzepatide in Mounjaro vs. Zepbound) may be covered for diabetes but not for
weight loss, because plans treat these as different indications with different coverage rules.
Coverage for Diabetes: More Consistent
If you have type 2 diabetes and your doctor prescribes Ozempic, Mounjaro, or another
GLP-1 for diabetes management, coverage is more likely. Most commercial health plans
and Medicare Part D formularies include at least one GLP-1 for diabetes, though
prior authorization is common and step therapy (trying other medications first)
may be required. Your out-of-pocket cost depends on your plan’s drug tier
for the specific medication — GLP-1s are typically Tier 3 or Tier 4, meaning
significant cost-sharing.
Coverage for Weight Loss: Highly Variable
Medicare Part D is prohibited by law from covering weight loss drugs (though the
Treat and Reduce Obesity Act, if passed, would change this). Medicaid coverage
varies by state. Commercial insurance coverage for Wegovy and Zepbound is
increasingly common among large employer plans (roughly 40–50% of large
employers cover weight loss drugs as of 2025), but marketplace plans and smaller
employer plans rarely include this coverage due to cost concerns.
Even when plans cover weight loss GLP-1s, they typically require BMI thresholds
(usually 30+ or 27+ with a comorbidity), prior authorization, and may have
quantity limits or step therapy requirements.
Manufacturer Savings Programs
Both Novo Nordisk (Wegovy/Ozempic) and Eli Lilly (Zepbound/Mounjaro) offer savings
cards and patient assistance programs that can reduce out-of-pocket costs significantly
for commercially insured patients. These savings programs do not apply to Medicare
or Medicaid patients. For commercially insured patients who meet eligibility
requirements, costs can be as low as $25–$99/month through these programs.